Quest Diagnostics Incorporated EBITDA for the Trailing 12 Months (TTM) ending June 30, 2025: USD 1.93 B

Quest Diagnostics Incorporated EBITDA is USD 1.93 B for the Trailing 12 Months (TTM) ending June 30, 2025, a 9.87% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Quest Diagnostics Incorporated EBITDA for the Trailing 12 Months (TTM) ending June 30, 2024 was USD 1.75 B, a 6.44% change year over year.
  • Quest Diagnostics Incorporated EBITDA for the Trailing 12 Months (TTM) ending June 30, 2023 was USD 1.65 B, a -34.16% change year over year.
  • Quest Diagnostics Incorporated EBITDA for the Trailing 12 Months (TTM) ending June 30, 2022 was USD 2.50 B, a -28.57% change year over year.
  • Quest Diagnostics Incorporated EBITDA for the Trailing 12 Months (TTM) ending June 30, 2021 was USD 3.50 B, a 136.17% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)